GFS Advisors LLC Buys New Holdings in Haleon plc (NYSE:HLN)

GFS Advisors LLC purchased a new position in shares of Haleon plc (NYSE:HLN) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 10,025 shares of the company’s stock, valued at approximately $96,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Caprock Group LLC lifted its stake in shares of Haleon by 13.8% in the fourth quarter. Caprock Group LLC now owns 43,566 shares of the company’s stock valued at $416,000 after buying an additional 5,299 shares in the last quarter. Baron Wealth Management LLC lifted its position in Haleon by 4.3% in the 4th quarter. Baron Wealth Management LLC now owns 33,632 shares of the company’s stock valued at $321,000 after acquiring an additional 1,381 shares in the last quarter. Hantz Financial Services Inc. lifted its position in Haleon by 43.0% in the 4th quarter. Hantz Financial Services Inc. now owns 604,946 shares of the company’s stock valued at $5,771,000 after acquiring an additional 182,015 shares in the last quarter. Stonegate Investment Group LLC boosted its stake in Haleon by 23.1% during the 4th quarter. Stonegate Investment Group LLC now owns 46,428 shares of the company’s stock valued at $443,000 after purchasing an additional 8,720 shares during the last quarter. Finally, Blue Trust Inc. increased its holdings in Haleon by 19.2% during the 4th quarter. Blue Trust Inc. now owns 47,876 shares of the company’s stock worth $507,000 after purchasing an additional 7,703 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Morgan Stanley downgraded shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Three research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Haleon has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Price Performance

Shares of NYSE HLN opened at $9.47 on Friday. The company has a market capitalization of $42.85 billion, a PE ratio of 27.84, a PEG ratio of 2.71 and a beta of 0.29. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The stock’s 50 day moving average price is $9.54 and its 200-day moving average price is $9.75. Haleon plc has a twelve month low of $7.89 and a twelve month high of $10.80.

Haleon (NYSE:HLN) last posted its quarterly earnings data on Thursday, October 31st. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.03. The business had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.74 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. During the same quarter in the previous year, the firm earned $0.10 earnings per share. On average, equities analysts anticipate that Haleon plc will post 0.43 EPS for the current year.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.